Concordia's $3.5B Deal Grows Rare Disease Drug Portfolio
Concordia Healthcare Corp. on Tuesday said that it inked a $3.5 billion deal, including debt, for private equity-backed Amdipharm Mercury Ltd., as the Toronto-listed pharmaceutical company looks to grow its portfolio...To view the full article, register now.
Already a subscriber? Click here to view full article